• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail
-

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.

Links

Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Show All Studies
Export to ExcelExport to Excel
General
Application Number P070008
Most Recent Protocol Version Approved 11/06/2008
Study Name CELESTIAL Study
Study Status Progress Adequate
General Study Protocol Parameters
Study Design Prospective Cohort Study
Study involve follow-up of premarket cohort (Y/N) No
Data Source Sponsor Registry
Comparison Group Objective Performance Criterion
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description This study is a 5-year, multi-center prospective cohort study designed to follow at least 2,000   show the rest ...
Study Population Description The study includes patients who require treatment for advanced heart failure through any CRT-P or   show the rest ...
Sample Size 2,000 patients, 75 sites
Data Collection Primary Endpoint 1 evaluates the overall incidence of serious adverse events related to the Corox   show the rest ...
Followup Visits and Length of Followup Patients will be seen for routine follow-up visits per their institutional standard of care (typically   show the rest ...


CELESTIAL Study Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Reporting Status
1 year report 05/12/2009 05/08/2009 On Time
18 month report 11/10/2009 11/06/2009 On Time
2 year report 05/12/2010 05/07/2010 On Time
30 month report 11/10/2010 11/08/2010 On Time
3 year report 05/12/2011 05/10/2011 On Time
42 month report 11/10/2011 11/07/2011 On Time
4 year report 05/11/2012 05/08/2012 On Time
54 month report 11/09/2012 11/08/2012 On Time
5 year report 05/11/2013 05/07/2013 On Time
66 month report 11/09/2013 11/06/2013 On Time
6 year report 05/11/2014    

Show All Studies

-
-